Immune thrombocytopenia management during COVID-19 pandemic: An Italian monocentric experience

EJHaem. 2022 Mar 9;3(2):453-456. doi: 10.1002/jha2.406. eCollection 2022 May.

Abstract

Over the last 2 years, different cases of immune thrombocytopenia (ITP) in patients affected by SARS-CoV2 have been reported. The management of SARS-CoV2 in subjects with simultaneous or previous ITP can be challenging because of the great involvement of the haemostatic system in this viral infection. In this report, we describe the management and outcome of patients with newly diagnosed (ND), chronic and previous ITP, infected by COVID-19, referred to the Haematology Institute of University Hospital Policlinico Umberto I in Rome. Steroids + immunoglobulins for ND or relapsed ITP and continuation of home therapy for chronic ITP are advised, although further knowledge is required.

Keywords: COVID‐19; ITP; SARS‐CoV2; management; therapy.